The selective class III/V receptor tyrosine kinase inhibitor SU11657 inhibits tumor growth and angiogenesis in experimental neuroblastomas grown in mice

Pediatric Research

Volumn 57, Issue 5 I, 2005, Pages 690-695

  Bäckman, Ulrika ^a   Christofferson, Rolf ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR BB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR; SU 11657; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SELECTIVITY; HUMAN; HUMAN CELL; MALE; MOUSE; NEUROBLASTOMA; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SOLID TUMOR; TUMOR VASCULARIZATION; TUMOR VOLUME; TUMOR XENOGRAFT;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; NEUROBLASTOMA; ORGANIC CHEMICALS; PLATELET-DERIVED GROWTH FACTOR; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; STEM CELL FACTOR; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 17744394494     PISSN: 00313998     EISSN: None     Source Type: Journal    
DOI: 10.1203/01.PDR.0000156508.68065.AA     Document Type: Article

References (30)

1. Maris JM, Matthay KK 1999 Molecular biology of neuroblastoma. J Clin Oncol 17:2264-2279
2. Evans AE, D'Angio GJ, Propert K, Anderson J, Hann HW 1987 Prognostic factors in neuroblastoma. Cancer 59:1853-1859
3. Komuro H, Kaneko S, Kaneko M, Nakanishi Y 2001 Expression of angiogenic factors and tumor progression in human neuroblastoma. J Cancer Res Clin Oncol 127:739-743
4. Eggert A, Ikegaki N, Kwiatkowski J, Zhao H, Brodeur GM, Himelstein BP 2000 High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastoma. Clin Cancer Res 6:1900-1908
5. Strawn LM, McMahon G, App H, Schreck R, Kuchler WR, Longhi MP, Hui TH, Tang C, Levitzki A, Gazit A, Chen I, Keri G, Orfi L, Risau W, Flamme I, Ullrich A, Hirth KP, Shawver LK 1996 Flk-1 as a target for tumor growth inhibition. Cancer Res 56:3540-3545
6. Fukuzawa M, Sugiura H, Koshinaga T, Ikeda T, Hagiwara N, Sawada T 2002 Expression of vascular endothelial growth factor and its receptor Flk-1 in human neuroblastoma using in situ hybridization. J Pediatr Surg 37:1747-1750
7. Pietras K, Östman A, Sjöquist M, Buchdunger E, Reed RK, Heldin CH, Rubin K 2001 Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 61:2929-2934
8. Matsui T, Sano K, Tsukamoto T, Ito M, Takaishi T, Nakata H, Nakamura H, Chihara K 1993 Human neuroblastoma cells express alpha and beta platelet-derived growth factor receptors coupling with neurotrophic and chemotactic signaling. J Clin Invest 92:1153-1160
9. Shawver LK, Lipson KE, Pong TAT, McMahon G, Plowman GD, Strawn LM 1997 Receptor tyrosine kinases as targets for inhibition of angiogenesis. Drug Discov Today 2:50-63
10. Ikeda H, Kanakura Y, Tamaki TKuriu A, Kitayama H, Ishikawa J, Kanayama Y, Yonezawa T, Tarui S, Griffin JD 1991 Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells. Blood 78:2962-2968
11. Cohen PS, Chan JP, Lipkunskaya M, Biedler JL, Seeger RC 1994 Expression of stem cell factor and c-kit in human neuroblastoma. The Children's Cancer Group. Blood 84:3465-3472
12. Timeus F, Crescenzio N, Vallo P, Pistamiglio P, Pigliano M, Garelli E, Ricotti E, Rocchi P, Strippoli P, Cordero di Montezemolo L, Madon E, Ramenghi U, Basso G 1997 Stem cell factor suppresses apoptosis in neuroblastoma cell lines. Exp Hematol 25:1253-1260
13. Zhang W, Stoica G, Tasca SI, Kelly K, Meininger CJ 2000 Modulation of tumor angiogenesis by stem cell factor. Cancer Res 60:6757-6762
14. Timeus F, Ricotti E, Crescenzio N, Garelli E, Doria A, Spinelli M, Ramenghi U, Basso G 2001 Flt-3 and its ligand are expressed in neural crest-derived tumors and promote survival and proliferation of their cell lines. Lab Invest 7:1025-1037
15. Sohal J, Phan VT, Chan PV, Davis EM, Patel B, Kelly LM, Abrams TJ, O'Farrell AM, Gilliland DG, Le Beau MM, Kogan SC 2003 A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657. Blood 101:3188-3197
16. Bäckman U, Svensson Å, Christofferson R 2002 Importance of vascular endothelial growth factor A in the progression of experimental neuroblastoma. Angiogenesis 5:267-274
17. Wassberg E, Hedborg F, Sköldenberg EG, Stridsberg M, Christofferson RH 1999 Inhibition of angiogenesis induces chromaffin differentiation and apoptosis in neuroblastoma. Am J Pathol 154:395-403
18. Look AT, Hayes FA, Shuster JJ, Douglass EC, Castleberry RP, Bowman LC, Smith EI, Brodeur GM 1991 Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 9:581-591
19. Ribatti D, Raffaghello L, Pastorino F, Nico B, Brignole C, Vacca A, Ponzoni M 2002 In vivo angiogenic activity of human neuroblastoma correlates with MYCN oncogene overexpression. Int J Cancer 102:351-354
20. Meitar D, Crawford SE, Rademaker AW, Cohen SL 1996 Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma. J Clin Oncol 14:305-314
21. Hanahan D, Folkman J 1996 Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-364
22. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH 1994 Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 43:26988-29995
23. Fong TA, Shawver LK, Sun L, Tang C, App H, Powell TJ, Kim YH, Schreck R, Wang X, Risau W, Ullrich A, Hirth KP, McMahon G 1999 SU5416 is a potent selective inhibitor of the vascular endothelial growth factor receptor (Flk-I/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 59:99-106
24. Marx M, Perlmutter RA, Madri JA 1994 Modulation of platelet-derived growth factor receptor expression in microvascular endothelial cells during in vitro angiogenesis. J Clin Invest 93:131-139
25. Takase H, Oemar BS, Pech M, Luscher TF 1999 Platelet-derived growth factor-induced vasodilation in mesenteric resistance arteries by nitric oxide: blunted response in spontaneous hypertension. J Cardiovasc Pharmacol 33:223-228
26. de Jong JS, Diest PJ, van der Valk P, Baak JP 1998 Expression of growth factors, growth inhibiting factors, and their receptor in invasive breast cancer. I: an inventory in search of autocrine and paracrine loops. J Pathol 184:44-52
27. Folkman J 1996 Tumor angiogenesis and tissue factor. Nat Med 2:167-168
28. Kim E, Serur A, Huang J, Manley CA, McCrudden KW, Frischer JS, Soffer SZ, Ring L, New T, Zabski S, Rudge JS, Holash J, Yancopoulos GD, Kandel JJ, Yamashiro DJ 2002 Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc Natl Acad Sci USA 99:11399-11404
29. Meister B, Grunebach F, Bautz F, Brugger W, Fink FM, Kanz L, Mohle R 1999 Expression of vascular endothelial growth factor (VEGF) and its receptors in human neuroblastoma. Eur J Cancer 35:445-449
30. Pietras K, Rubin K, Sjöblom T, Buchdunger E, Sjöquist M, Heldin CH, Östman A 2002 Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 62:5476-5484